Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine + Atropine vs Ketorolac for PDPH Prevention
NCT06729047Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Countries
- 1
- Sponsor
- Assiut University
- Modality
- Small Molecules
- Drugs
- neostigmine
- Conditions
- post-dural puncture headache (PDPH)
01
Overview
Phase 2, randomised trial of neostigmine in post-dural puncture headache (PDPH) (3 arms), sponsored by Assiut University. Primary endpoint: Post-dural puncture headache at 1 week. Planned start Dec 2024; status: not yet recruiting.
02
Design
3 arms- Study design
- Randomized
Placebo
Patients receive normal saline
Neostigmine + Atropine
Patients receive neostigmine plus atropine
Ketorolac
Patients receive ketorolac
03
Who it enrols
Patients with BMI < 35 kg/m2, ASA physical status I or II, scheduled for infraumbilical surgeries, excluding those with cognitive impairment, pregnancy, or abnormal body temperature.
04
Endpoints
Primary
Post-dural puncture headache
Beyond the preview
Go deeper on NCT06729047.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06729047.